Medical/Pharmaceuticals
OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
SHANGHAI, Dec. 4, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a$100 million Series A financing closed in June 2025. The rou...
2025-12-05 09:00
2763
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initia...
2025-12-05 07:38
3044
Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)
Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of ...
2025-12-04 21:04
2787
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development
HMI-115 received FDA Fast Track Designation based on results from a Phase II clinical trial for endometriosis Mean dysmenorrhea pain score reduced by 42% Mean non-menstrual chronic pelvic pain score reduced by 52% Most patients maintained normal menstrual cycles No typical peri-menopausal sympt...
2025-12-04 20:08
5359
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR...
2025-12-04 19:50
4815
UMED Wins CES Innovation Awards® 2026, Redefining Bladder Care with World's First Automated Irrigation System
Transforming bladder care from hospital-centered procedures to accessible, data-driven digital urology SEOUL, South Korea, Dec. 4, 2025 /PRNewswire/ -- UMED Inc, an AI-driven urology-focused healthcare startup, announced that its automated bladder irrigation system, UroRinse™ Light, has been nam...
2025-12-04 15:08
1943
Menarini Asia-Pacific Expands Production Facilities, Strengthening Indonesia's Role as Regional Manufacturing Hub
* Menarini announces the expansion of MiLab facilities in Cikarang, including a new warehouse andenhanced production facility to meet growing export demands. * Another milestone includes the projected export of up to 700,000 units of Dermatix products toChina alone this year. * The event hig...
2025-12-04 14:30
2436
HiroPharmaConsulting (R) Granted Patent for AI-enabled Reliability Assurance Method for Pharmacovigilance Systems
OSAKA, Japan, Dec. 4, 2025 /PRNewswire/ -- HiroPharmaConsulting (R) Co., Ltd. announced that it has received a patent for an innovative Good Pharmacovigilance Practice (GVP) Computerized System Validation (CSV) methodology designed to ensure the reliability of pharmacovigilance systems equipped ...
2025-12-04 14:00
1961
Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the appointment of Dr.Hongjiang Miao as Chief AI Offic...
2025-12-04 10:01
2821
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of annualAsia-Pacific meeting in Singapore SINGAPORE, Dec. 4, 2025 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) today launched its call for abstracts for i...
2025-12-04 10:00
4340
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
NANJING, China and GAITHERSBURG, Md., Dec. 3, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Adm...
2025-12-04 09:57
2210
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical...
2025-12-04 08:00
3170
POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results
GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced its unaudited financial results for the six months endedJune 30, 2025. Mr. Zhenyang Shi, Chairma...
2025-12-04 05:15
5270
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response
and Enable Patient Stratification for Drug Development.
PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire/ -- ImpriMed
2025-12-04 01:00
2139
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs
Accomplished biotech and CRO leader brings 25+ years of global oncology drug
development and operational excellence to propel Emerald's continued growth.
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- Emerald
2025-12-03 21:10
2280
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong . These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lym...
2025-12-03 17:00
3335
S3 Connected Health Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity
Recognized for pioneering advancements that redefine medical device
connectivity, accelerate home-based care, and deliver transformative value
across global healthcare ecosystems.
SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ -- Frost & Sullivan
2025-12-03 16:00
1778
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- MediThinQ
2025-12-03 09:00
3692
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
* FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases * OMLYCLO® (omalizumab-igec) is the first and only ...
2025-12-03 08:43
4980
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM -- PREVIOUSLY SHOWN TO IMPROVE COGNITION -- MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary
studies -
Key Takeaways
* Findings from three NIA-funded ancillary studies to the U.S. POINTER trial
2025-12-03 03:00
2943
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
58123
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
52850
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
51202
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
20636
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
15883